医薬品薬事市場の規模、シェア、動向分析レポート：サービスプロバイダ別、サービス別、カテゴリー別、適応症別、開発段階別、企業規模別、地域別、セグメント予測、2025年～2030年

医薬品薬事の市場成長と動向

Grand View Research, Inc.の最新レポートによると、世界の医薬品薬事市場規模は2030年までに143億4,000万米ドルに達し、2025～2030年のCAGRは7.17％を記録すると予測されています。

市場成長を牽引する主要要因は、規制状況の変化と、個別化医療、バイオシミラー、希少疾病用医薬品などの新興セグメントの成長です。FDAの医薬品承認プロセスには大きな変化が生じています。最近、21世紀治療法案が可決され、特定タイプの医薬品に対するFDAの承認プロセスが迅速化されることが期待されています。

FDAは、4つのプログラム（Accelerated Approval、Priority Review、Fast Track、Breakthrough Therapy）を開始し、重篤で生命を脅かす疾患に対する医薬品の審査を迅速化しています。これらのプログラムによる医薬品は、規制当局によってより早く承認されます。さらに英国では、画期的な新薬への患者アクセスを迅速化するための政府主導の取り組みであるThe Accelerated Access Collaborativeが開始され、同国における新規治療の入手可能性とアクセシビリティの向上が期待されています。このような承認プロセスの変化により、技術革新が促進され、世界の最近の承認プロセスの変化に精通した薬事サービスプロバイダーへの需要が高まると予想されます。

バイオシミラー、希少疾病用医薬品、個別化医薬品、コンパニオン診断薬、適応検査デザイン、その他の製品市場の成長に伴い、これらのセグメントにおける医薬品薬事の専門性に対する需要は増加すると予想されます。企業が異業種に進出し、法規制順守の負担の増大に直面するにつれ、薬事業務の専門知識を有する専門サービスプロバイダーへの需要が高まっています。特に新興経済諸国では、政府からの資金援助によって希少疾病用医薬品の開発が大幅に加速しています。

市場開拓のため、複数の企業が提携、買収、新製品開発に取り組んでいます。例えば、フレイアは2022年10月に韓国の整形外科用インプラント製造会社と提携し、契約に基づき、規制機器登録と法的代理サービスを提供しました。さらに、2022年1月にはParexel International CorporationがRegulatory &Access Consulting Organizationを設立しました。この組織は、臨床検査の初期段階から薬事サポートを提供するために設立されました。

医薬品薬事市場レポートハイライト

• カテゴリー別では、医薬品セグメントが2024年に55.36%を超える最大の収益シェアを占めました。人口増加、都市化の進展、質の高い医療に対する国内需要の高まりにより、革新的な医薬品を開発・製造する製薬企業に大きな可能性が生まれている
• カテゴリー別では、マラリア、HIV/AIDS、非感染性疾患などの疾病の蔓延により、生物製剤セグメントが予測期間中に最速のCAGR 9.07%を記録すると予測されています。
• 適応症別では、がん領域が2024年の市場を独占しています。製薬企業やバイオ医薬品企業の強力な免疫学パイプラインは、同セグメントの成長をさらに押し上げると予想されます。
• 2024年の市場シェアは、がん領域が32.98%で最大となりました。これは、がんの罹患率が高く、安全で効果的な治療オプションへのニーズが高まっているためと考えられます。
• 開発段階別では、臨床研究セグメントが2024年に最大の市場シェアを占めました。これは、臨床検査の登録件数が増加していることに起因しており、このセグメントの成長を促進すると予想されます。
• 前臨床検査セグメントは、予測期間中にCAGR 8.40%と最も速い速度で成長すると予測されています。がん、CVDs、神経疾患などの既存疾患の有病率の増加が市場成長を促進する要因です。
• サービスプロバイダー別では、薬事業務のアウトソーシングセグメントが2024年に59.07%と最大の市場シェアを占め、予測期間中のCAGRは8.76%と最速になると予想されます。こうしたサービスの人気が高まっている背景には、アウトソーシングによって医療企業がコストを削減できることがあり、これが市場成長の主要要因となっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 医薬品薬事市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 補助市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• サービスギャップ分析
  • 市場機会
  • 市場課題分析
• 臨床検査量分析、2024年
  • 地域別臨床検査総数（2024年）
  • 臨床検査の総数（相別）（2024年）
  • 臨床検査の総数（研究デザイン別）（2024年）
  • 主要治療領域別臨床検査総数（2024年）
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析
• 医薬品薬事サービスに関するベストプラクティスとケーススタディ

第4章 医薬品薬事市場：サービスプロバイダー別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場規模と動向分析、サービスプロバイダー、2018～2030年
• 社内
• アウトソーシング

第5章 医薬品薬事市場：サービス別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場規模と動向分析、サービス、2018～2030年
• 規制コンサルティング
• 法的代理
• 規制文書の執筆と出版
  • 書き込み
  • 出版
• 製品登録と臨床検査申請
• その他

第6章 医薬品薬事市場：カテゴリー別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場規模と動向分析、カテゴリー、2018～2030年
• 薬剤
  • イノベーター
  • ジェネリック
• 生物製剤
  • バイオテクノロジー
  • ATMP
  • バイオシミラー

第7章 医薬品薬事市場：適応症別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場の規模と動向分析、適応症、2018～2030年
• 腫瘍学
• 神経学
• 心臓病学
• 免疫学
• その他

第8章 医薬品薬事市場：開発段階別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場の規模と動向分析、開発段階、2018～2030年
• 前臨床
• 臨床研究
• 市販後承認（PMA）

第9章 医薬品薬事市場：企業規模別、推定・動向分析

• セグメントダッシュボード
• 世界の医薬品薬事市場変動分析
• 世界の医薬品薬事市場規模と動向分析、企業規模、2018～2030年
• 小
• 中
• 大

第10章 医薬品薬事市場：地域別、推定・動向分析

• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • ノルウェー
  • オランダ
  • スイス
  • スウェーデン
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • インドネシア
  • マレーシア
  • シンガポール
  • タイ
  • 台湾
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • コロンビア
  • チリ
• 中東
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • エジプト
  • イスラエル
• アフリカ
  • 南アフリカ
  • ボツワナ
  • ナミビア
  • ジンバブエ
  • ザンビア
  • タンザニア
  • ルワンダ
  • ガーナ
  • ナイジェリア
  • ウガンダ
  • モーリシャス
  • ケニア

第11章 競合情勢

• 市場参入企業の分類
  • マーケットリーダー
  • 新興参入企業
• 競合市場評価分析（2024年）
• 企業プロファイル
  • Freyr
  • IQVIA Inc.
  • ICON plc.
  • WuXi AppTec（WAI）
  • Charles River Laboratories International, Inc.
  • Labcorp Drug Development
  • Parexel International Corporation
  • Pharmalex GmbH
  • Pharmexon
  • Genpact

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 4 Global Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 5 Global Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 6 Global Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 7 Global Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 8 Global Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 9 Global Pharmaceutical Regulatory Affairs, by Region, 2018 - 2030 (USD Million)
• Table 10 North America Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 11 North America Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 12 North America Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 13 North America Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 14 North America Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 15 North America Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 16 North America Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 17 U.S. Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 18 U.S. Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 19 U.S. Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 20 U.S. Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 21 U.S. Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 22 U.S. Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 23 Canada Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 24 Canada Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 25 Canada Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 26 Canada Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 27 Canada Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 28 Canada Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 29 Mexico Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 30 Mexico Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 31 Mexico Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 32 Mexico Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 33 Mexico Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 34 Mexico Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 35 Europe Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 36 Europe Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 37 Europe Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 38 Europe Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 39 Europe Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 40 Europe Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 41 Europe Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 42 UK Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 43 UK Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 44 UK Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 45 UK Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 46 UK Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 47 UK Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 48 Germany Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 49 Germany Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 50 Germany Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 51 Germany Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 52 Germany Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 53 Germany Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 54 France Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 55 France Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 56 France Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 57 France Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 58 France Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 59 France Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 60 Italy Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 61 Italy Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 62 Italy Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 63 Italy Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 64 Italy Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 65 Italy Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 66 Spain Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 67 Spain Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 68 Spain Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 69 Spain Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 70 Spain Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 71 Spain Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 72 Denmark Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 73 Denmark Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 74 Denmark Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 75 Denmark Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 76 Denmark Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 77 Denmark Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 78 Norway Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 79 Norway Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 80 Norway Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 81 Norway Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 82 Norway Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 83 Norway Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 84 The Netherlands Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 85 The Netherlands Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 86 The Netherlands Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 87 The Netherlands Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 88 The Netherlands Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 89 The Netherlands Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 90 Switzerland Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 91 Switzerland Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 92 Switzerland Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 93 Switzerland Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 94 Switzerland Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 95 Switzerland Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 96 Sweden Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 97 Sweden Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 98 Sweden Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 99 Sweden Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 100 Sweden Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 101 Sweden Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 102 Asia Pacific Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 103 Asia Pacific Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 104 Asia Pacific Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 105 Asia Pacific Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 106 Asia Pacific Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 107 Asia Pacific Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 108 Asia Pacific Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 109 Japan Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 110 Japan Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 111 Japan Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 112 Japan Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 113 Japan Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 114 Japan Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 115 China Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 116 China Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 117 China Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 118 China Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 119 China Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 120 China Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 121 India Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 122 India Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 123 India Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 124 India Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 125 India Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 126 India Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 127 Australia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 128 Australia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 129 Australia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 130 Australia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 131 Australia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 132 Australia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 133 South Korea Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 134 South Korea Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 135 South Korea Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 136 South Korea Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 137 South Korea Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 138 South Korea Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 139 Indonesia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 140 Indonesia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 141 Indonesia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 142 Indonesia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 143 Indonesia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 144 Indonesia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 145 Malaysia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 146 Malaysia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 147 Malaysia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 148 Malaysia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 149 Malaysia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 150 Malaysia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 151 Singapore Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 152 Singapore Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 153 Singapore Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 154 Singapore Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 155 Singapore Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 156 Singapore Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 157 Thailand Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 158 Thailand Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 159 Thailand Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 160 Thailand Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 161 Thailand Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 162 Thailand Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 163 Taiwan Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 164 Taiwan Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 165 Taiwan Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 166 Taiwan Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 167 Taiwan Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 168 Taiwan Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 169 Latin America Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 170 Latin America Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 171 Latin America Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 172 Latin America Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 173 Latin America Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 174 Latin America Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 175 Latin America Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 176 Brazil Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 177 Brazil Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 178 Brazil Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 179 Brazil Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 180 Brazil Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 181 Brazil Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 182 Argentina Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 183 Argentina Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 184 Argentina Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 185 Argentina Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 186 Argentina Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 187 Argentina Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 188 Colombia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 189 Colombia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 190 Colombia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 191 Colombia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 192 Colombia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 193 Colombia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 194 Chile Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 195 Chile Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 196 Chile Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 197 Chile Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 198 Chile Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 199 Chile Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 200 Middle East Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 201 Middle East Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 202 Middle East Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 203 Middle East Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 204 Middle East Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 205 Middle East Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 206 Middle East Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 207 Saudi Arabia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 208 Saudi Arabia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 209 Saudi Arabia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 210 Saudi Arabia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 211 Saudi Arabia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 212 Saudi Arabia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 213 UAE Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 214 UAE Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 215 UAE Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 216 UAE Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 217 UAE Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 218 UAE Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 219 Kuwait Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 220 Kuwait Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 221 Kuwait Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 222 Kuwait Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 223 Kuwait Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 224 Kuwait Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 225 Egypt Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 226 Egypt Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 227 Egypt Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 228 Egypt Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 229 Egypt Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 230 Egypt Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 231 Israel Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 232 Israel Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 233 Israel Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 234 Israel Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 235 Israel Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 236 Israel Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 237 Africa Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
• Table 238 Africa Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 239 Africa Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 240 Africa Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 241 Africa Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 242 Africa Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 243 Africa Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 244 South Africa Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 245 South Africa Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 246 South Africa Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 247 South Africa Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 248 South Africa Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 249 South Africa Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 250 Botswana Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 251 Botswana Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 252 Botswana Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 253 Botswana Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 254 Botswana Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 255 Botswana Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 256 Namibia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 257 Namibia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 258 Namibia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 259 Namibia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 260 Namibia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 261 Namibia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 262 Zimbabwe Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 263 Zimbabwe Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 264 Zimbabwe Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 265 Zimbabwe Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 266 Zimbabwe Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 267 Zimbabwe Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 268 Zambia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 269 Zambia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 270 Zambia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 271 Zambia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 272 Zambia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 273 Zambia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 274 Tanzania Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 275 Tanzania Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 276 Tanzania Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 277 Tanzania Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 278 Tanzania Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 279 Tanzania Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 280 Rwanda Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 281 Rwanda Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 282 Rwanda Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 283 Rwanda Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 284 Rwanda Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 285 Rwanda Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 286 Ghana Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 287 Ghana Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 288 Ghana Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 289 Ghana Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 290 Ghana Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 291 Ghana Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 292 Nigeria Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 293 Nigeria Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 294 Nigeria Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 295 Nigeria Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 296 Nigeria Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 297 Nigeria Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 298 Uganda Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 299 Uganda Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 300 Uganda Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 301 Uganda Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 302 Uganda Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 303 Uganda Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 304 Mauritius Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 305 Mauritius Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 306 Mauritius Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 307 Mauritius Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 308 Mauritius Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 309 Mauritius Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
• Table 310 Kenya Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
• Table 311 Kenya Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
• Table 312 Kenya Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
• Table 313 Kenya Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
• Table 314 Kenya Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
• Table 315 Kenya Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Pharmaceutical Regulatory Affairs, Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 Regional Marketplace: Key Takeaways
• Fig. 12 Global Pharmaceutical Regulatory Affairs, for In-house, 2018 - 2030 (USD Million)
• Fig. 13 Global Pharmaceutical Regulatory Affairs, for Outsourcing, 2018 - 2030 (USD Million)
• Fig. 14 Global Pharmaceutical Regulatory Affairs, for Regulatory Consulting, 2018 - 2030 (USD Million)
• Fig. 15 Global Pharmaceutical Regulatory Affairs, for Legal Representation , 2018 - 2030 (USD Million)
• Fig. 16 Global Pharmaceutical Regulatory Affairs, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
• Fig. 17 Global Pharmaceutical Regulatory Affairs, for Writing, 2018 - 2030 (USD Million)
• Fig. 18 Global Pharmaceutical Regulatory Affairs, for Publishing, 2018 - 2030 (USD Million)
• Fig. 19 Global Pharmaceutical Regulatory Affairs, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
• Fig. 20 Global Pharmaceutical Regulatory Affairs, for Other Services, 2018 - 2030 (USD Million)
• Fig. 21 Global Pharmaceutical Regulatory Affairs, for Drugs, 2018 - 2030 (USD Million)
• Fig. 22 Global Pharmaceutical Regulatory Affairs, for Innovator Drugs, 2018 - 2030 (USD Million)
• Fig. 23 Global Pharmaceutical Regulatory Affairs, for Preclinical Innovator Drugs, 2018 - 2030 (USD Million)
• Fig. 24 Global Pharmaceutical Regulatory Affairs, for Clinical Innovator Drugs, 2018 - 2030 (USD Million)
• Fig. 25 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Innovator Drugs, 2018 - 2030 (USD Million)
• Fig. 26 Global Pharmaceutical Regulatory Affairs, for Generics Drugs, 2018 - 2030 (USD Million)
• Fig. 27 Global Pharmaceutical Regulatory Affairs, for Preclinical Generics Drugs, 2018 - 2030 (USD Million)
• Fig. 28 Global Pharmaceutical Regulatory Affairs, for Clinical Generics Drugs, 2018 - 2030 (USD Million)
• Fig. 29 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Generics Drugs, 2018 - 2030 (USD Million)
• Fig. 30 Global Pharmaceutical Regulatory Affairs, for Biologics, 2018 - 2030 (USD Million)
• Fig. 31 Global Pharmaceutical Regulatory Affairs, for Biotech, 2018 - 2030 (USD Million)
• Fig. 32 Global Pharmaceutical Regulatory Affairs, for Preclinical Biotech, 2018 - 2030 (USD Million)
• Fig. 33 Global Pharmaceutical Regulatory Affairs, for Clinical Biotech, 2018 - 2030 (USD Million)
• Fig. 34 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Biotech, 2018 - 2030 (USD Million)
• Fig. 35 Global Pharmaceutical Regulatory Affairs, for ATMP, 2018 - 2030 (USD Million)
• Fig. 36 Global Pharmaceutical Regulatory Affairs, for Preclinical ATMP, 2018 - 2030 (USD Million)
• Fig. 37 Global Pharmaceutical Regulatory Affairs, for Clinical ATMP, 2018 - 2030 (USD Million)
• Fig. 38 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) ATMP, 2018 - 2030 (USD Million)
• Fig. 39 Global Pharmaceutical Regulatory Affairs, for Biosimilars, 2018 - 2030 (USD Million)
• Fig. 40 Global Pharmaceutical Regulatory Affairs, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
• Fig. 41 Global Pharmaceutical Regulatory Affairs, for Clinical Biosimilars, 2018 - 2030 (USD Million)
• Fig. 42 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Biosimilars, 2018 - 2030 (USD Million)
• Fig. 43 Global Pharmaceutical Regulatory Affairs, for Oncology, 2018 - 2030 (USD Million)
• Fig. 44 Global Pharmaceutical Regulatory Affairs, for Neurology, 2018 - 2030 (USD Million)
• Fig. 45 Global Pharmaceutical Regulatory Affairs, for Cardiology, 2018 - 2030 (USD Million)
• Fig. 46 Global Pharmaceutical Regulatory Affairs, for Immunology, 2018 - 2030 (USD Million)
• Fig. 47 Global Pharmaceutical Regulatory Affairs, for Others, 2018 - 2030 (USD Million)
• Fig. 48 Global Pharmaceutical Regulatory Affairs, for Preclinical, 2018 - 2030 (USD Million)
• Fig. 49 Global Pharmaceutical Regulatory Affairs, for Clinical, 2018 - 2030 (USD Million)
• Fig. 50 Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA), 2018 - 2030 (USD Million)
• Fig. 51 Global Pharmaceutical Regulatory Affairs, for Small, 2018 - 2030 (USD Million)
• Fig. 52 Global Pharmaceutical Regulatory Affairs, for Medium, 2018 - 2030 (USD Million)
• Fig. 53 Global Pharmaceutical Regulatory Affairs, for Large, 2018 - 2030 (USD Million)
• Fig. 54 Regional Outlook, 2024 & 2030
• Fig. 55 North America Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 56 US Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Canada Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Mexico Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Europe Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 60 UK Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Germany Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 62 France Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Italy Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Spain Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Denmark Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Norway Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Netherlands Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Switzerland Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Sweden Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Asia Pacific Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Japan Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 72 China Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 73 India Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Australia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 75 South Korea Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Indonesia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Malaysia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Singapore Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Thailand Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Taiwan Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Latin America Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Brazil Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Argentina Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Colombia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Chile Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Middle East Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Saudi Arabia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 88 UAE Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Kuwait Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Egypt Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Israel Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Africa Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 93 South Africa Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Botswana Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Namibia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Zimbabwe Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Zambia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Tanzania Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Rwanda Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Ghana Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Nigeria Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Uganda Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Mauritius Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Kenya Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Pharmaceutical Regulatory Affairs Market Growth & Trends:

The global pharmaceutical regulatory affairs market size is expected to reach USD 14.34 billion by 2030, registering a CAGR of 7.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are the changing regulatory landscape and growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs. There have been significant changes to the FDA's drug approval processes. Recently, the 21st Century Cures bill was passed, which is expected to speed up the approval process of the FDA for certain types of drugs.

The FDA has launched four programs-Accelerated Approval, Priority Review, Fast Track, and Breakthrough Therapy-to expedite drug reviews for serious and life-threatening diseases. The medicines under these programs are approved faster by regulatory agencies. In addition, in the UK, the launch of The Accelerated Access Collaborative, a government initiative to fast-track patient access to potential breakthrough medicines, is anticipated to boost the availability and accessibility of novel therapies in the country. These changes in approval processes are expected to drive innovation and increase the demand for regulatory service providers who are well-acquainted with recent changes in approval processes globally.

The demand for regulatory specialization in these fields is anticipated to increase with the growth of the markets for biosimilar, orphan medications, personalized medicines, companion diagnostics, adaptive trial designs, and other products. Demand for specialized service providers with expertise in regulatory affairs is increasing as companies expand into different industries and face a growing burden of regulatory compliance. Government financing has considerably accelerated the development of orphan medications, particularly in industrialized economies.

Several companies are involved in collaborations, acquisitions, and new product development to gain a position in the market. For instance, in October 2022, Freyr partnered with an orthopedic implant manufacturing company in Korea, and as per the agreement, provided it with regulatory device registration and legal representation services. Moreover, in January 2022, Parexel International Corporation formed a Regulatory & Access Consulting Organization. This organization was established to provide regulatory support to clinical studies from the early stages.

Pharmaceutical Regulatory Affairs Market Report Highlights:

• In terms of category, the drug segment held the largest revenue share of over 55.36% in 2024. The growing population, increasing urbanization, and rising demand for quality healthcare in the country have created a significant potential for pharmaceutical companies that develop and manufacture innovative drugs
• Based on category, the biologics segment is anticipated to register the fastest CAGR of 9.07% over the forecast period owing to the prevalence of diseases such as malaria, HIV/AIDS, and non-communicable diseases
• In terms of indication, the oncology segment dominated the market in 2024. The robust immunology pipeline of pharmaceutical and biopharmaceutical companies is anticipated to further boost segment growth
• The oncology segment dominated the market in 2024 with the largest revenue share of 32.98%. This can be attributed to the high prevalence of cancer, which is boosting the need for safe and effective treatment options
• In terms of development stage, the clinical studies segment held the largest market share in 2024. This can be attributed to the increasing number of clinical trial registrations, which is expected to drive the segment growth
• The preclinical segment is projected to grow at the fastest CAGR of 8.40% during the forecast period. Increasing prevalence of existing diseases such as cancer, CVDs, & neurological diseases are factors driving the market growth
• In terms of service providers, the outsourced regulatory affairs segment held the largest market share in 2024 at 59.07% and is anticipated to witness the fastest CAGR of 8.76% over the forecast period. The increasing popularity of these services can be attributed to the fact that outsourcing enables healthcare companies to reduce costs, which is a major contributing factor to market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Regulatory Affairs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Changing Regulatory Landscape
    • 3.2.1.2. Life Sciences Companies Focusing on Their Core Competencies
    • 3.2.1.3. Economic and Competitive Pressures
    • 3.2.1.4. Demand for the Faster Approval Process for Breakthrough Drugs and Devices
    • 3.2.1.5. Entry of Companies into the Global Market
    • 3.2.1.6. Growth in Emerging Areas such as Personalized Medicine, Biosimilars, and Orphan Drugs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Risk Associated with Data Security
    • 3.2.2.2. Monitoring Issues and Lack of Standardization
• 3.3. Service Gap Analysis
  • 3.3.1. Market Opportunities
    • 3.3.1.1. Service Upgrade
    • 3.3.1.2. Technological Advancements
    • 3.3.1.3. Latest Trends
  • 3.3.2. Market Challenges Analysis
    • 3.3.2.1. Analysis Pertaining to Existing Gaps & Shortcomings in the Regulatory Services
    • 3.3.2.2. Bottlenecks Faced by Companies Seeking Regulatory Approvals or Maintaining Compliance
• 3.4. Clinical Trials Volume Analysis, 2024
  • 3.4.1. Total Number of Clinical Trials, by Region (2024)
  • 3.4.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.4.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.4.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis
• 3.6. Best Practices and Case Study Pertaining to Regulatory Affairs Services

Chapter 4. Pharmaceutical Regulatory Affairs Market: Service Provider Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 4.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
• 4.4. In-house
  • 4.4.1. In-house Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 4.5. Outsourcing
  • 4.5.1. Outsourcing Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Regulatory Affairs Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 5.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 5.4. Regulatory Consulting
  • 5.4.1. Regulatory Consulting Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.5. Legal Representation
  • 5.5.1. Legal Representation Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.6. Regulatory Writing & Publishing
  • 5.6.1. Regulatory Writing & Publishing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.6.2. Writing
    • 5.6.2.1. Writing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.6.3. Publishing
    • 5.6.3.1. Publishing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.7. Product Registration & Clinical Trial Applications
  • 5.7.1. Product Registration & Clinical Trial Applications Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 5.8. Other Services
  • 5.8.1. Other Services Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Regulatory Affairs Market: Category Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 6.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
• 6.4. Drugs
  • 6.4.1. Drugs Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.4.2. Innovator
    • 6.4.2.1. Innovator Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.2.2. Preclinical
      • 6.4.2.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.2.3. Clinical
      • 6.4.2.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.2.4. Post Market Approval (PMA)
      • 6.4.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Generics
    • 6.4.3.1. Generics Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.3.2. Preclinical
      • 6.4.3.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.3.3. Clinical
      • 6.4.3.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.4.3.4. Post Market Approval (PMA)
      • 6.4.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 6.5. Biologics
  • 6.5.1. Biologics Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5.2. Biotech
    • 6.5.2.1. Biotech Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.2.2. Preclinical
      • 6.5.2.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.2.3. Clinical
      • 6.5.2.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.2.4. Post Market Approval (PMA)
      • 6.5.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5.3. ATMP
    • 6.5.3.1. ATMP Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.3.2. Preclinical
      • 6.5.3.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.3.3. Clinical
      • 6.5.3.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.3.4. Post Market Approval (PMA)
      • 6.5.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5.4. Biosimilars
    • 6.5.4.1. Biosimilars Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.4.2. Preclinical
      • 6.5.4.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.4.3. Clinical
      • 6.5.4.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 6.5.4.4. Post Market Approval (PMA)
      • 6.5.4.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical Regulatory Affairs Market: Indication Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 7.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Indication, 2018 to 2030 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.5. Neurology
  • 7.5.1. Neurology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.6. Cardiology
  • 7.6.1. Cardiology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.7. Immunology
  • 7.7.1. Immunology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 7.8. Others
  • 7.8.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical Regulatory Affairs Market: Development Stage Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 8.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Development Stage, 2018 to 2030 (USD Million)
• 8.4. Preclinical
  • 8.4.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.5. Clinical studies
  • 8.5.1. Clinical Studies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 8.6. Post Market Approval (PMA)
  • 8.6.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Pharmaceutical Regulatory Affairs Market: Company Size Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
• 9.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Company Size, 2018 to 2030 (USD Million)
• 9.4. Small
  • 9.4.1. Small Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.5. Medium
  • 9.5.1. Medium Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 9.6. Large
  • 9.6.1. Large Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 10. Pharmaceutical Regulatory Affairs Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Global Regional Market Snapshot
• 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.4. North America
  • 10.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.4.2. U.S.
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.4.3. Canada
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.4.4. Mexico
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 10.5. Europe
  • 10.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.2. UK
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.3. Germany
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.4. France
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.5. Italy
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.6. Spain
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.7. Denmark
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.8. Norway
    • 10.5.8.1. Key Country Dynamics
    • 10.5.8.2. Competitive Scenario
    • 10.5.8.3. Regulatory Framework
    • 10.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.9. The Netherlands
    • 10.5.9.1. Key Country Dynamics
    • 10.5.9.2. Competitive Scenario
    • 10.5.9.3. Regulatory Framework
    • 10.5.9.4. The Netherlands Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.10. Switzerland
    • 10.5.10.1. Key Country Dynamics
    • 10.5.10.2. Competitive Scenario
    • 10.5.10.3. Regulatory Framework
    • 10.5.10.4. Switzerland Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5.11. Sweden
    • 10.5.11.1. Key Country Dynamics
    • 10.5.11.2. Competitive Scenario
    • 10.5.11.3. Regulatory Framework
    • 10.5.11.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.2. Japan
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Framework
    • 10.6.2.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.3. China
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Framework
    • 10.6.3.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.4. India
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Competitive Scenario
    • 10.6.4.3. Regulatory Framework
    • 10.6.4.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.5. Australia
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Competitive Scenario
    • 10.6.5.3. Regulatory Framework
    • 10.6.5.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.6. South Korea
    • 10.6.6.1. Key Country Dynamics
    • 10.6.6.2. Competitive Scenario
    • 10.6.6.3. Regulatory Framework
    • 10.6.6.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.7. Indonesia
    • 10.6.7.1. Key Country Dynamics
    • 10.6.7.2. Competitive Scenario
    • 10.6.7.3. Regulatory Framework
    • 10.6.7.4. Indonesia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.8. Malaysia
    • 10.6.8.1. Key Country Dynamics
    • 10.6.8.2. Competitive Scenario
    • 10.6.8.3. Regulatory Framework
    • 10.6.8.4. Malaysia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.9. Singapore
    • 10.6.9.1. Key Country Dynamics
    • 10.6.9.2. Competitive Scenario
    • 10.6.9.3. Regulatory Framework
    • 10.6.9.4. Singapore Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.10. Thailand
    • 10.6.10.1. Key Country Dynamics
    • 10.6.10.2. Competitive Scenario
    • 10.6.10.3. Regulatory Framework
    • 10.6.10.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6.11. Taiwan
    • 10.6.11.1. Key Country Dynamics
    • 10.6.11.2. Competitive Scenario
    • 10.6.11.3. Regulatory Framework
    • 10.6.11.4. Taiwan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 10.7. Latin America
  • 10.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7.2. Brazil
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Framework
    • 10.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7.3. Argentina
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Framework
    • 10.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7.4. Colombia
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Framework
    • 10.7.4.4. Colombia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7.5. Chile
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Framework
    • 10.7.5.4. Chile Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 10.8. Middle East
  • 10.8.1. Middle East Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8.2. Saudi Arabia
    • 10.8.2.1. Key Country Dynamics
    • 10.8.2.2. Competitive Scenario
    • 10.8.2.3. Regulatory Framework
    • 10.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8.3. UAE
    • 10.8.3.1. Key Country Dynamics
    • 10.8.3.2. Competitive Scenario
    • 10.8.3.3. Regulatory Framework
    • 10.8.3.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8.4. Kuwait
    • 10.8.4.1. Key Country Dynamics
    • 10.8.4.2. Competitive Scenario
    • 10.8.4.3. Regulatory Framework
    • 10.8.4.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8.5. Egypt
    • 10.8.5.1. Key Country Dynamics
    • 10.8.5.2. Competitive Scenario
    • 10.8.5.3. Regulatory Framework
    • 10.8.5.4. Egypt Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8.6. Israel
    • 10.8.6.1. Key Country Dynamics
    • 10.8.6.2. Competitive Scenario
    • 10.8.6.3. Regulatory Framework
    • 10.8.6.4. Israel Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 10.9. Africa
  • 10.9.1. Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.2. South Africa
    • 10.9.2.1. Key Country Dynamics
    • 10.9.2.2. Competitive Scenario
    • 10.9.2.3. Regulatory Framework
    • 10.9.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.3. Botswana
    • 10.9.3.1. Key Country Dynamics
    • 10.9.3.2. Competitive Scenario
    • 10.9.3.3. Regulatory Framework
    • 10.9.3.4. Botswana Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.4. Namibia
    • 10.9.4.1. Key Country Dynamics
    • 10.9.4.2. Competitive Scenario
    • 10.9.4.3. Regulatory Framework
    • 10.9.4.4. Namibia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.5. Zimbabwe
    • 10.9.5.1. Key Country Dynamics
    • 10.9.5.2. Competitive Scenario
    • 10.9.5.3. Regulatory Framework
    • 10.9.5.4. Zimbabwe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.6. Zambia
    • 10.9.6.1. Key Country Dynamics
    • 10.9.6.2. Competitive Scenario
    • 10.9.6.3. Regulatory Framework
    • 10.9.6.4. Zambia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.7. Tanzania
    • 10.9.7.1. Key Country Dynamics
    • 10.9.7.2. Competitive Scenario
    • 10.9.7.3. Regulatory Framework
    • 10.9.7.4. Tanzania Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.8. Rwanda
    • 10.9.8.1. Key Country Dynamics
    • 10.9.8.2. Competitive Scenario
    • 10.9.8.3. Regulatory Framework
    • 10.9.8.4. Rwanda Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.9. Ghana
    • 10.9.9.1. Key Country Dynamics
    • 10.9.9.2. Competitive Scenario
    • 10.9.9.3. Regulatory Framework
    • 10.9.9.4. Ghana Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.10. Nigeria
    • 10.9.10.1. Key Country Dynamics
    • 10.9.10.2. Competitive Scenario
    • 10.9.10.3. Regulatory Framework
    • 10.9.10.4. Nigeria Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.11. Uganda
    • 10.9.11.1. Key Country Dynamics
    • 10.9.11.2. Competitive Scenario
    • 10.9.11.3. Regulatory Framework
    • 10.9.11.4. Uganda Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.12. Mauritius
    • 10.9.12.1. Key Country Dynamics
    • 10.9.12.2. Competitive Scenario
    • 10.9.12.3. Regulatory Framework
    • 10.9.12.4. Mauritius Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.9.13. Kenya
    • 10.9.13.1. Key Country Dynamics
    • 10.9.13.2. Competitive Scenario
    • 10.9.13.3. Regulatory Framework
    • 10.9.13.4. Kenya Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Market Participant Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Competitive Market Assessment Analysis (2024)
• 11.3. Company Profiles
  • 11.3.1. Freyr
    • 11.3.1.1. Company Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. IQVIA Inc.
    • 11.3.2.1. Company Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. ICON plc.
    • 11.3.3.1. Company Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. WuXi AppTec (WAI)
    • 11.3.4.1. Company Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. Charles River Laboratories International, Inc.
    • 11.3.5.1. Company Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. Labcorp Drug Development
    • 11.3.6.1. Company Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. Parexel International Corporation
    • 11.3.7.1. Company Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. Pharmalex GmbH
    • 11.3.8.1. Company Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Pharmexon
    • 11.3.9.1. Company Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. Genpact
    • 11.3.10.1. Company Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives